Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

SML2487

Sigma-Aldrich

Cabazitaxel

≥95% (HPLC)

Sinônimo(s):

1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-[[(tert-butoxy)carbonyl]amino]-2-hydroxy-3-phenylpropanoate], DEP cabazitaxel, Jevtana, TXD 258, XRP 6258, XRP-6258, dimethoxydocetaxel

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

5 MG
R$ 585,00
25 MG
R$ 2.358,00

R$ 585,00

Check Cart for Availability
Solicite uma grande encomenda
Todas as fotos(1)

Selecione um tamanho

Alterar visualização
5 MG
R$ 585,00
25 MG
R$ 2.358,00

About This Item

Fórmula empírica (Notação de Hill):
C45H57NO14
Número CAS:
183133-96-2
Peso molecular:
835.93
Número MDL:
MFCD18827611
Código UNSPSC:
12352200
NACRES:
NA.77

R$ 585,00

Check Cart for Availability
Solicite uma grande encomenda

Ensaio

≥95% (HPLC)

Formulário

powder

atividade óptica

[α]/D -36 to -44°, c = 0.5 in methanol

cor

white to beige

solubilidade

DMSO: 2 mg/mL, clear

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

N([C@H]([C@@H](O)C(=O)O[C@H]2C[C@]3([C@H]([C@@H]5[C@]6([C@H](OC6)C[C@@H]([C@]5(C(=O)[C@@H](C(=C2C)C3(C)C)OC)C)OC)OC(=O)C)OC(=O)c4ccccc4)O)c1ccccc1)C(=O)OC(C)(C)C

InChI

1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1

chave InChI

BMQGVNUXMIRLCK-OAGWZNDDSA-N

Ações bioquímicas/fisiológicas

Cabazitaxel is a synthetic taxane microtubule inhibitor and anticancer agent. It acts by stabilization of microtubules, promoting tubulin assembly into microtubules but inhibiting disassembly, resulting in the inhibition of mitotic and interphase cellular functions.
Synthetic taxane microtubule inhibitor

Pictogramas

Health hazardExclamation mark
GHS08,GHS07

Palavra indicadora

Warning

Classificações de perigo

Acute Tox. 4 Oral - Muta. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 2

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
0000279142
0000279143
0000284938
0000288313
0000288314

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Patricia Vrignaud et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 19(11), 2973-2983 (2013-04-17)
Taxanes are important chemotherapeutic agents with proven efficacy in human cancers, but their use is limited by resistance development. We report here the preclinical characteristics of cabazitaxel (XRP6258), a semisynthetic taxane developed to overcome taxane resistance. Cabazitaxel effects on purified
Sheel A Patel et al.
OncoTargets and therapy, 10, 4089-4098 (2017-09-02)
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are now multiple effective and approved agents for
Maria J Martinez et al.
iScience, 26(9), 107681-107681 (2023-09-14)
Men with incurable castration resistant prostate cancer (CRPC) are typically treated with taxanes; however, drug resistance rapidly develops. We previously identified a clinically relevant seven gene network in aggressive CRPC, which includes the spindle assembly checkpoint (SAC) kinase BUB1. Since
Takeo Kosaka et al.
Cancer chemotherapy and pharmacology, 82(6), 1061-1066 (2018-10-05)
The correlation of the oncological outcomes of docetaxel and cabazitaxel in Japanese metastatic castration-resistant prostate cancer (mCRPC) patients has not been unclear. This study included a total of 47 consecutive Japanese mCRPC patients treated with cabazitaxel and assessed the prognostic
Buse Cevatemre et al.
Cell death & disease, 15(2), 132-132 (2024-02-13)
The development of taxane resistance remains a major challenge for castration resistant prostate cancer (CR-PCa), despite the effectiveness of taxanes in prolonging patient survival. To uncover novel targets, we performed an epigenetic drug screen on taxane (docetaxel and cabazitaxel) resistant

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica